StreetAlpha.app
Home › Stocks › RARE

Ultragenyx Pharmaceutical Inc. (RARE)

Healthcare
$16.48
▼ −4.30%
LAST CLOSE · NOV 20

Ultragenyx is a pharmaceutical company in Novato, California, developing drug and gene therapy candidates for disease states. It last closed at $16.48 on Nov 20, down 4.30% on the day. The next earnings report for RARE is expected around Mon, Jan 11, 2027. For the quarter ended Sep 2026, RARE reported EPS of -$1.16 on revenue of $173.0M, with revenue up 8.1% from a year ago. Over its last 8 reports the stock moved an average of 5.1% the session after earnings. Over the last 12 months RARE insiders bought $0 of stock on the open market and sold $3.8M, according to SEC Form 4 filings.

AI Auto Pilots
Is RARE in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold RARE.

Key Stats

Last 12 months
Results
Revenue
$730.0M
+15.8% vs a year ago
Net income
−$524.0M
−71.8% margin
EPS (diluted)
−$5.17
Free cash flow
−$442.0M
−60.5% margin
Valuation
Market cap
$1.7B
101.9M shares
P/E
–
No P/E while losing money
Price to sales
2.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$150.0M
At Sep 30
Shareholder equity
−$376.0M
Shares outstanding
101.9M
At Oct 29
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $351.4M$351.4MFY2021FY2022: $363.3M$363.3MFY2022FY2023: $434.0M$434.0MFY2023FY2024: $560.0M$560.0MFY2024FY2025: $673.0M$673.0MFY2025

From RARE's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · Time not announced
Reported EPS
-$1.16
Quarter ended Sep 2026
Year ago EPS
-$1.81
Same quarter last year
Revenue
$173.0M
+8.1% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$1.38Dec '24Mar 2025: -$1.57Mar '25Jun 2025: -$1.17Jun '25Sep 2025: -$1.81Sep '25Dec 2025: -$1.28Dec '25Mar 2026: -$1.84Mar '26Jun 2026: -$0.90Jun '26Sep 2026: -$1.16Sep '26Latest -$1.16
Revenue by quarter
Dec 2024: $164.6MDec '24Mar 2025: $139.0MMar '25Jun 2025: $167.0MJun '25Sep 2025: $160.0MSep '25Dec 2025: $207.0MDec '25Mar 2026: $136.0MMar '26Jun 2026: $214.0MJun '26Sep 2026: $173.0MSep '26Latest $173.0M
How RARE moved after its last 8 reports
Average move the session after a report ±5.1%
Nov 3, 2026After the close+3.2%
Aug 4, 2026After the close−3.4%
May 5, 2026After the close+3.7%
Feb 12, 2026After the close−12.7%
Jan 12, 2026Time not announced+8.3%
Nov 4, 2025After the close−1.8%
Aug 5, 2025After the close−3.0%
May 6, 2025After the close−4.7%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on RAREStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on RARE
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on RARE

Technical Analysis

RARE · as of the Nov 20 close · updated each morning
Bounce inside a longer downtrend

The stock sits between its 20 and 50 day averages. It is 36% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 51). The nearest support is the Pivot S1 at $16.15, and the nearest resistance the Pivot at $16.75.

Short trendBullish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityHigh, 5.4%/day
Key levels
$39.8952 week high+142.1%
$22.34200 day average+35.6%
$20.92100 day average+26.9%
$17.08Pivot R1+3.6%
$16.77Swing high (Nov 11)+1.8%
$16.75Pivot+1.6%
$16.4820 day average+0.0%
$16.48Last close
$16.15Pivot S1−2.0%
$15.65Swing low (Nov 17)−5.0%
$15.5150 day average−5.9%
$12.7352 week low−22.8%
Indicators
RSI (14)50.64Middle of its rangeNeutral
MACD0.19Above its signal lineBullish
Stochastic70.7Middle of its rangeNeutral
ADX (14)19.6No clear trend
Williams %R-55.3Oversold below −80, overbought above −20Neutral
CCI (20)44.7Oversold below −100, overbought above 100Neutral
Rate of change+6.8%Change over 10 sessionsBullish
ATR (14)$0.90Typical daily range, 5.4% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Below
MA 200Below
What happened before, for RARE

What happened before

See how RARE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow RARE usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How RARE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for RAREHow many large options trades hit RARE, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

RARE Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●154 buying vs 169 selling
  • ▼Held by funds -1.9 pts
  • ▼Funds holding -43
  • ▲Superinvestors: 4 added, 1 cut
  • ▲Put/call 1.10 to 0.26
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding269312−13.8%
In funds' top 1048−50.0%
Held by funds103.0%104.9%−1.9 pts
New / increased45 / 10957 / 116−11.0%
Reduced / sold out85 / 8498 / 47+16.6%
Put/call ratio0.261.10−76.8%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RARE institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

RARE Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$3.8M25 sales · 9 insiders
35% of the selling was under pre-arranged trading plans.
2025-12 sold $115K2026-01 sold $72K2026-02 sold $72K2026-03 sold $2.5M2026-04 sold $98K2026-05 sold $269K2026-06 sold $207K2026-07 sold $156K2026-08 sold $164K2026-09 sold $20K2026-10 sold $108KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 15Howard HornCFOSale7,066$15.27$108K
Sep 15Theodore Alan HuizengaSVP, Chief Accounting OfficerSale plan1,283$13.57$17K
Sep 3Theodore Alan HuizengaSVP, Chief Accounting OfficerSale161$13.99$2K
Aug 3Howard HornCFOSale plan4,696$24.92$117K
Aug 3Karah Herdman ParschauerEVP and Chief Legal OfficerSale plan1,900$24.92$47K
Jul 1Howard HornCFOSale plan4,698$33.13$156K
Every insider buy and sale for RARE over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See RARE insider trades →

From SEC Form 4 filings by RARE's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RARE is in one of them and how their past RARE trades turned out.

RARE in the AI portfolios
Loading…

RARE News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RARE in an article yet. Here's the latest on the wider market.

RARE in the news

RARE Congress Trades

All congress trades →
Trades, 12 months
3
Buys
3
100%
Sells
0
0%
People
1
Last filed Oct 12
Who traded RARE · since 2025
Latest 5 filings
$1K – $15KTraded Sep 29, 2026Filed Oct 12, 2026
$1K – $15KTraded Mar 3, 2026Filed Apr 7, 2026
$1K – $15KTraded Feb 18, 2026Filed Mar 9, 2026
$1K – $15KTraded Aug 8, 2025Filed Sep 12, 2025
$1K – $15KTraded Jul 15, 2025Filed Aug 14, 2025
PersonTypeAmountTradedFiledDelay
Gilbert CisnerosD · CABuy$1K – $15KSep 29, 2026Oct 12, 202613 d
Gilbert CisnerosD · CABuy$1K – $15KMar 3, 2026Apr 7, 202635 d
Gilbert CisnerosD · CABuy$1K – $15KFeb 18, 2026Mar 9, 202619 d
Gilbert CisnerosD · CABuy$1K – $15KAug 8, 2025Sep 12, 202535 d
Gilbert CisnerosD · CABuy$1K – $15KJul 15, 2025Aug 14, 202530 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Ultragenyx Pharmaceutical

Ultragenyx is a pharmaceutical company based in Novato, California. It is developing drug candidates, including gene therapy candidates that use AAV vectors, for a range of disease states. Its work is aimed at patients, physicians and healthcare providers who would use any approved treatments, and it works with regulators such as the FDA and the EMA to define approval paths.

Headquarters
Novato, CA